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Takeda  pharmaceuticals), which do not share the hepatotoxic pro-
ﬁ  le of troglitazone (Scheen, 2001), were released and continue to be 
prescribed today in the management of type II diabetes. In more 
recent years, the focus on PPARγ has intensiﬁ  ed, as new ligands 
and novel biological roles have emerged for the receptor, particu-
larly for its therapeutic potential in neurodegenerative disorders, 
such as Alzheimer’s disease (AD). Previous excellent reviews have 
highlighted the beneﬁ  ts of PPARγ activation for the treatment of 
AD (Landreth et al., 2008; Jiang et al., 2008). The present review 
incorporates both supportive and contradictory evidence for the 
beneﬁ  cial role of PPARγ ligands on afﬂ  icted neuronal, glial, and 
notably, cerebrovascular networks in AD. Gaps in our knowledge 
are addressed, and the value of PPARγ agonists as future AD thera-
peutics is discussed, in view of the latest clinical trials.
MECHANISM OF ACTION
Peroxisome proliferator-activated receptors are members of the 
nuclear receptor superfamily, an evolutionarily conserved family 
of receptors that also includes the thyroid, estrogen, and gluco-
corticoid receptors, each playing vital roles in development, endo-
crine signaling and metabolism. There are 48 nuclear receptors in 
humans, and PPARs belong to the class of ligand-dependent recep-
tors (24) that convey a variety of hormonal and metabolic signals 
directly to the genome by activating or repressing transcription 
via their ligand-binding (LBD) and DNA-binding (DBD) domains 
(Nagy and Schwabe, 2004). The remaining receptors comprise the 
orphan receptors, for which ligands are unknown or may not exist 
(‘true orphans’) or are only recently being   discovered (‘adopted 
INTRODUCTION
In the 1960s and 1970s, a class of hepatocarcinogens that caused 
peroxisome proliferation in the liver of mice and rats, while exerting 
lipid-lowering effects, was discovered (Hess et al., 1965; Svoboda 
and Azarnoff, 1966; Reddy and Krishnakantha, 1975). A couple 
of decades later, the molecular target of these agents was identi-
ﬁ  ed as a member of the nuclear hormone receptor superfamily, 
and termed ‘peroxisome proliferator-activated receptor’ (PPAR) 
(Issemann and Green, 1990). Three PPAR isoforms (α, γ, and β/δ), 
each encoded by a different gene, were subsequently characterized 
in mammals (Chen et al., 1993; Zhu et al., 1993; Kliewer et al., 
1994; Tontonoz et al., 1994) and in Xenopus laevis (Dreyer et al., 
1992). PPARα was the receptor responsible for the hypolipidemic 
and peroxisome proliferative effects initially observed in rodents, 
and PPARδ corresponded to the Xenopus PPARβ, hence the mixed 
β/δ nomenclature. The search for the natural ligands of PPARs 
pointed to fatty acids and eicosanoids derived from the diet or 
metabolism (Issemann et al., 1993; Kliewer et al., 1997), which ﬁ  t 
nicely with the proposed role of PPARs in regulating lipid storage 
and glucose homeostasis following dietary intake. Concurrently, 
PPARγ was identiﬁ  ed as the receptor mediating the insulin sensitiz-
ing effects of a class of oral anti-diabetics, the thiazolidinediones 
(TZDs) that were being tested in rodent models of non-insulin 
dependent diabetes (Lehmann et al., 1995). TZDs were commer-
cialized in the late nineties. However, the ﬁ  rst of these, troglitazone 
(Rezulin), caused severe liver failure and was quickly withdrawn 
from the UK, US and Japanese markets. Soon thereafter, rosigli-
tazone (Avandia®, GlaxoSmithKline) and pioglitazone (Actos®, 
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orphans’) (Germain et al., 2006). Upon binding ligand, PPARs 
heterodimerize with the common retinoid X receptor (RXR, 
Issemann et al., 1993), and recruit coregulators and chromatin-
modifying enzymes to speciﬁ  c DNA sequences, termed peroxisome 
proliferator response elements (PPREs), in the promoters of target 
genes (coregulator biology reviewed in McKenna and O’Malley, 
2002). Normally, non-liganded receptor is constitutively associ-
ated with corepressors, for example, nuclear receptor corepressor 
(NCoR). These recruit histone deacetylase complexes that gener-
ate a condensed chromatin structure over the target promoter, 
effectively blocking the transcriptional machinery in a process 
called transcriptional repression. When ligand binds, the recep-
tor undergoes a conformational change, causing corepressors to 
dissociate and coactivators to bind, resulting in transcriptional 
activation. Coactivators such as cAMP response element-binding 
protein (CBP) and p300 are thought to act as histone acetyltrans-
ferases that cause chromatin decondensation to prepare promot-
ers for the recruitment of the RNA polymerase. The exchange of 
corepressors and coactivators deﬁ  nes a highly dynamic cycle of 
transcriptional modulation (Nagy and Schwabe, 2004). Finally, 
many nuclear receptors can regulate gene programs, not only by 
interaction with their speciﬁ  c targets, but through cross-talk with 
other signal transduction pathways, in a process called transrepres-
sion. Accumulating evidence suggests that PPARs can inhibit gene 
expression through this mechanism, by interfering with activator 
protein-1 (AP-1) and nuclear factor-kappaB (NF-κB) activities 
(Ricote et al., 1998; Pascual et al., 2005). Transrepression can be 
achieved through PPARγ sequestration of NF-κB or of the lim-
ited pool of coactivators available to NF-κB-dependent promot-
ers. A more detailed account of transrepression mechanisms can 
be found in Jiang et al. (2008) and references therein. It is worth 
mentioning that PPAR ligands exert many of their biological 
actions without binding to their receptor, through direct interac-
tions with mitochondrial proteins or smooth muscle ion channels, 
for example (Zhang et al., 1994; Chawla et al., 2001; Ryan et al., 
2004). The pervasiveness of such receptor-independent effects is a 
topic of ongoing investigations, and has been reviewed elsewhere 
(Feinstein et al., 2005).
Relevance for Alzheimer’s disease
Alzheimer’s disease is characterized by a gradual failure of memory, 
language, orientation and judgment underlined by dysfunctional 
synapses and neuronal loss (Cummings, 2004). Its diagnosis is con-
ﬁ  rmed postmortem by the presence of amyloid-beta (Aβ) plaques 
and neuroﬁ  brillary tangles in the brain, respectively composed 
of aggregated Aβ derived from the amyloid precursor protein 
(APP) and of the hyperphosphorylated microtubule-associated 
protein tau (τ). At the site of plaques are activated microglial and 
astroglial cells secreting cytokines and chemokines that contrib-
ute to an inﬂ  ammatory and pro-oxidant environment (Akiyama 
et al., 2000; Butterﬁ  eld et al., 2001; Selkoe, 2001). AD patients also 
characteristically feature a decrease in basal cerebral glucose utili-
zation (CGU) in parietotemporal and posterior cingulate cortex 
(Fukuyama et al., 1994; Mosconi et al., 2004; Langbaum et al., 
2009), altered neurometabolic coupling (Melrose et al., 2009), and 
reduced levels and activity of the endothelial glucose transporter 
1 (GLUT-1) that delivers glucose to the brain from the blood 
(Kalaria and Harik, 1989; Simpson et al., 1994). More recently, 
the hypothesis that AD represents a state of diabetes unique to 
the central nervous system (CNS) or type III diabetes was put 
forth (de la Monte et al., 2006), whereby insulin resistance and 
altered insulin receptor signaling in neurons would be expected 
to interfere with synaptic plasticity (Zhao et al., 2004). In support 
of this claim, intranasal insulin administration improved verbal 
recall in a subgroup of AD patients, suggesting a therapeutic 
potential of insulin sensitizers, like TZDs, in AD (Reger et al., 
2008). Invariably, AD is marked by chronic resting hypoperfusion 
(Farkas and Luiten, 2001; Bell and Zlokovic, 2009), and a limited 
ability of the cerebral circulation to match the needs of activated 
neurons, that is, impaired neurovascular coupling or functional 
hyperemia (Hock et al., 1997; Rosengarten et al., 2006). As the 
brain has both high energy demands and no fuel reserves, these 
conditions threaten basic brain function and disrupt protein syn-
thesis underlying learning (Hermann et al., 2001; Iadecola, 2004). 
Finally, AD brain vessels display structural alterations, ranging 
from Aβ deposition on small to medium arteries (cerebral amyloid 
angiopathy, CAA, Roher et al., 1993), and cholinergic deafferen-
tation (Tong and Hamel, 1999), to accumulation of extracellular 
matrix (ECM) proteins, such as collagen, in vascular basement 
membranes (Christov et al., 2008), resulting in vascular ﬁ  brosis. 
The latter has been ascribed to increased levels of the ECM organ-
izer, transforming growth factor-beta 1 (TGF-β1) in AD brain and 
vessels (Wyss-Coray et al., 1997; Grammas and Ovase, 2002), and 
of its effector molecules, endothelin-1 (ET-1) and connective tis-
sue growth factor (CTGF) (Clozel and Salloukh, 2005). Thus, the 
pathological alterations are numerous in the AD brain, but as the 
following sections will show, PPARγ activation can counter many 
of these in both animal models and AD patients.
ANTI-INFLAMMATORY EFFECTS
Aside from its function in lipid and glucose metabolism, one of 
the new and now well-documented roles attributed to PPARγ 
was the ability to silence inﬂ   ammatory gene expression in 
peripheral immune cells producing natural PPARγ ligands, like 
15-deoxy-Δ;12,14 prostaglandin J2 (15d-PGJ2) (Jiang et al., 1998; 
Ricote et al., 1998). Around the same time, non-steroidal anti-
inﬂ  ammatory drugs (NSAIDs), such as indomethacin, ibuprofen, 
and fenoprofen, that had been associated with decreased AD risk 
(McGeer et al., 1990; In’t Veld et al., 2001), were demonstrated to 
be PPARγ ligands (Lehmann et al., 1997). Furthermore, expression 
of the receptor was documented, not only in peripheral organs, but 
also in the CNS (Moreno et al., 2004; Inestrosa et al., 2005) and 
human brain microvessels (Ramirez et al., 2008), with a report of 
increased protein levels in the postmortem AD cortex (Kitamura 
et al., 1999). Collectively, this led to the idea that PPARγ could 
be an important target for brain inﬂ  ammation in AD. Indeed, 
various PPARγ ligands, both natural (15d-PGJ2, docosahexaenoic 
acid) and synthetic (NSAIDs and TZDs), were shown to inhibit 
the expression of interleukin-6 (IL-6), tumor necrosis factor α 
(TNFα) and cyclooxygenase-2 (COX-2) from monocytic and 
microglial cell cultures stimulated with Aβ (Combs et al., 2000). 
Similar results were obtained in transgenic mice carrying vari-
ous mutations of human APP associated with early-onset familial 
AD. Studies in ∼10-month-old Tg2576 mice on 4- to 6-month Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 21  |  3
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the AD cerebrovascular   pathology (Wyss-Coray et al., 2000; Tong 
et al., 2005), PPARγ agonists pioglitazone and ibuprofen effectively 
reduced microglial and astrocyte activation (Lacombe et al., 2004; 
Nicolakakis et al., 2009) (Figure 1B).
PARADOXICAL EFFECTS ON AMYLOID PATHOLOGY
A major effort in AD research has been to counter the amyloid 
pathology that hallmarks the disease, especially to reduce high lev-
els of soluble Aβ oligomers shown detrimental to neuronal and 
synaptic function well before their assembly into parenchymal 
plaques (Hsia et al., 1999; Mucke et al., 2000; Lesné et al., 2008). 
To this end, several groups have investigated the effectiveness of 
PPARγ ligands against amyloidosis. Table 1 non-exhaustively sum-
marizes the somewhat conﬂ  icting results, which likely reﬂ  ect differ-
ences in model system (cell culture vs. in vivo), severity of deﬁ  cits, 
dose and duration of treatment or method of quantiﬁ  cation (e.g. 
ELISA, Western blot, immunohistochemistry). A more extensive 
review of NSAID effects in animal models and various cell lines, 
including those of neuronal origin, can be found in Gasparini et al. 
 ibuprofen  treatment reported reduced interleukin-1β (IL-1β) and 
glial ﬁ  brillary acidic protein (GFAP) levels (Lim et al., 2000), and 
decreased expression of the microglial markers of activation CD45 
and CD11b (Yan et al., 2003). In the latter study, pioglitazone, at 
a dose of 20 mg/kg/day, was ineffective. Yet in a subsequent study 
using twice the pioglitazone dose and an acute 7-day treatment, 
COX-2 and inducible nitric oxide synthase (iNOS) expression 
was attenuated in the cortex and hippocampus of 10-month-old 
APPV717I mice, and comparable results were seen with ibuprofen 
(Heneka et al., 2005) (Figure 1A). A recent study by our group 
employing a different transgenic APP model, but the original 
dose of Yan et al. (2003), corroborated the anti-  inﬂ  ammatory 
effects of pioglitazone: the percentage of cortex occupied by 
GFAP-immunoreactive astrocytes was signiﬁ  cantly reduced in 
∼15-month-old animals that had been treated for 6–8 weeks 
(Nicolakakis et al., 2008). Anti-inﬂ  ammatory effects of PPARγ 
agonists were also more recently conﬁ  rmed in various APP models 
(Escribano et al., 2010; Toledo and Inestrosa, 2010). In TGF-β1-
overexpressing transgenic (TGF) mice that reproduce elements of 
FIGURE 1 | Anti-inﬂ  ammatory effects of PPARγ agonists in transgenic 
mouse models of AD or of the cerebrovascular pathology of the disease. 
(A) Pioglitazone (Pio) and ibuprofen (Ibu) attenuated GFAP and iNOS expression 
in astrocytes of the hippocampus (HC) and frontal cortex (FC) of treated 
APPV717I mice. Bar, 50 µm. Reproduced with kind permission from Heneka 
et al. (2005) and Elsevier. (B) Pioglitazone countered microglial activation in TGF 
mice (T+) relative to age-matched controls (T−), as seen by the shrinking of the 
cell soma in animals treated for 2 months starting at 2 months of age. Bar, 
50 µm. Reproduced with permission from Lacombe et al. (2004) and BioMed 
Central publisher.Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 21  |  4
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on β- and/or γ-secretase promoters to alter the proteolytic release 
of Aβ from its precursor protein, APP (Eriksen et al., 2003; Heneka 
et al., 2005; Sastre et al., 2003, 2006). Also notable is the lack of 
studies investigating the effects of PPARγ ligands on vascular Aβ 
deposition, that is, CAA.
(2004). The NSAIDs in Table 1 were given at doses believed to 
activate PPARγ. Of note, NSAIDs were shown to be effective inde-
pendently of action on their classical targets, the COX enzymes, 
as evidenced in COX-1 and COX-2-deﬁ  cient mouse embryonic 
ﬁ  broblasts (Weggen et al., 2001). They likely acted through PPARγ 
Table 1 Effects of PPARγ ligands on amyloidosis in transgenic mice or APP-expressing cells.
Ligand Model  Sol  Aβ1–40 Sol  Aβ1–42 A β plaques  Reference
NSAIDS
Ibuprofen Tg2576  mice1 No  effect(Ø)† No  effect(Ø)†  ↓  Lim et al. (2000)
 Tg2576  mice2 No  effect  ↓ n/a*  Weggen et al. (2001)
 Tg2576  mice2 No  effect  ↓ n/a*  Eriksen et al. (2003)
 Tg2576  mice1  ↓  ↓  ↓  Yan et al. (2003)
 Tg2576  mice1  No effect  No effect  n/a*  Kotilinek et al. (2008)
 APPV717I  mice1  ↓ No  effect(↓)  ↓  Heneka et al. (2005)
  APPV717I mice1  No effect ‡  No effect ‡  n/a*  Sastre et al. (2006)
  HEK293 cells  No effect  No effect(↓) n/a  Yan et al. (2003)
 CHO  cells  n/a  ↓ n/a  Weggen et al. (2001)
  H4 cells  No effect  ↓ n/a  Eriksen et al. (2003)
Indomethacin Tg2576  mice3 No  effect  ↓ n/a*  Eriksen et al. (2003)
 Tg2576  mice4  ↓  ↓  ↓  Sung et al. (2004)
 CHO  cells  n/a  ↓ n/a  Weggen et al. (2001)
  H4 cells   No effect  ↓ n/a  Eriksen et al. (2003)
Sulindac Tg2576  mice2 No  effect  ↓ n/a*  Eriksen et al. (2003)
 CHO  cells  n/a  ↓ n/a  Weggen et al. (2001)
 HS683  cells  n/a  ↓ n/a  Weggen et al. (2001)
 COX−/− ﬁ  broblasts  n/a  ↓ n/a  Weggen et al. (2001)
  H4 cells  No effect  ↓ n/a    Eriksen et al. (2003)
Diclofenac  H4 cells  No effect  ↓ n/a  Eriksen et al. (2003)
 Tg2576  mice2 No  effect  ↓ n/a*  Eriksen et al. (2003)
Fenoprofen  H4 cells  No effect  ↓ n/a  Eriksen et al. (2003)
 Tg2576  mice2 No  effect  ↓ n/a*  Eriksen et al. (2003)
Meclofen  H4 cells  No effect  ↓ n/a  Eriksen et al. (2003)
 Tg2576  mice2  ↓  ↓ n/a*  Eriksen et al. (2003)
Flurbiprofen  H4 cells  No effect  ↓ n/a  Eriksen et al. (2003)
  CHO cells  No effect  ↓ n/a  Eriksen et al. (2003)
 Tg2576  mice2 No  effect  ↓ n/a*  Eriksen et al. (2003)
Piroxicam Tg2576  mice2 No  effect  (↓) n/a*  Eriksen et al. (2003)
Diﬂ  unisal  Tg2576 mice2 No  effect  ↓ n/a*  Eriksen et al. (2003)
TZDS
Pioglitazone N2a  cells  ↓  ↓ n/a  Sastre et al. (2003)
  HEK293 cells  No effect   No effect  n/a  Yan et al. (2003)
 HEK293  cells  Ø†  Ø† n/a Camacho et al. (2004)
 Tg2576  mice5  ↓ No  effect(↓)   No effect   Yan et al. (2003)
 APPV717I  mice6  No effect(↓)  ↓  ↓  Heneka et al. (2005)
 APPV717I  mice6  Ø‡  Ø‡ n/a*  Sastre et al. (2006)
  APPSwe,Ind mice5  No effect  No effect  No effect  Nicolakakis et al. (2008)
Troglitazone HEK293  cells  Ø†  Ø† n/a Camacho et al. (2004)
Rosiglitazone HEK293  cells  Ø†  Ø† n/a Camacho et al. (2004)
 Tg2576  mice7 No  effect  ↓  No effect   Pedersen et al. (2006)
 APPSwe,Ind mice7  ↓  ↓  ↓  Escribano et al. (2010)
 APP/PS18 n/a  n/a  ↓  Toledo and Inestrosa (2010)
Sol, soluble; n/a, not applicable; ↓ or Ø signiﬁ  cant decrease; (↓) or (Ø) non-signiﬁ  cant trend towards decrease; *mice treated at start of or prior to plaque deposition; 
†total soluble Aβ levels were reported; ‡total intracellular Aβ levels assessed by immunohistochemistry; 162.5 mg/kg/day; 250 mg/kg/day; 310 mg/kg/day; 410 mg/L in 
water; 520 mg/kg/day; 640 mg/kg/day; 7∼5 mg/kg/day; 83 mg/kg/day.Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 21  |  5
Nicolakakis and Hamel  PPARγ in AD therapy
RhoA activation (Keen et al., 2004; Ramirez et al., 2008; Huang 
et al., 2009), thus protecting levels of tight junction proteins, and 
countering leukocyte–endothelial interactions and blood–brain 
barrier (BBB) compromise that occur in AD (Fiala et al., 2002; 
Zipser et al., 2007). Finally, ligand effects independent of PPARγ 
activation could also contribute to protecting the AD cerebral cir-
culation; these include inhibition of the L-type Ca2+ current (Zhang 
et al., 1994) and opening of K+ channels (Nomura et al., 2008) in 
smooth muscle cells, promoting vasorelaxation.
Collectively, the evidence suggests that PPARγ ligands offer 
therapeutic potential against many aspects of the AD cerebrovas-
cular pathology. In aged APP mice, in vivo pioglitazone treatment 
rescued evoked cerebrovascular dilatations, basal availability of 
the vasodilator nitric oxide, as well as the neurovascular coupling 
response to whisker stimulation (Figure 2B). The improvements 
were accompanied by normalization of SOD2 levels in cerebral ves-
sels, a sensitive marker of oxidative stress (Nicolakakis et al., 2008). 
Arterial responsiveness and neurovascular coupling were similarly 
rescued by pioglitazone in aged TGF mice, even though vascular 
structure remained altered and antioxidants were ineffective (Tong 
et al., 2005; Nicolakakis et al., 2009). The latter ﬁ  ndings suggest 
that pioglitazone may be able to restore the function of an aged, 
ﬁ  brotic arterial tree that is insensitive to pure antioxidants. This 
may bear signiﬁ  cance for the AD cerebral circulation that is char-
acterized by aging, vascular wall thickening and TGF-β1 elevations 
(Grammas and Ovase, 2002). Recently, Sato et al. (2009) reported 
improved cerebral blood ﬂ  ow (CBF) in AD patients treated with 
pioglitazone (Figure 2C), positioning the TZD as a valuable tool 
against chronic hypoperfusion in AD, along with the cholineste-
rase inhibitors, the currently prescribed AD drugs that have been 
re-evaluated and also shown to restore basal and evoked perfusion 
responses (Rosengarten et al., 2006; Yoshida et al., 2007).
CEREBROVASCULAR PROTECTION
Peroxisome proliferator-activated receptorγ plays an integral role 
in maintaining cerebrovascular health. Its genetic inactivation 
in mice results in enhanced free radical generation, endothelial 
dysfunction and hypertrophy of cerebral arterioles (Beyer et al., 
2008; Ketsawatsomkron et al., 2010) (Figure 2A). Free radicals 
such as superoxide (O2
·−) are particularly deleterious for vascular 
function, as they sequester endothelium-derived vasodilators or 
disrupt smooth muscle ion channels, resulting in diminished dila-
tory ability. Accordingly, the use of TZDs to activate PPARγ can 
enhance antioxidant systems in human endothelial cells (Inoue 
et al., 2001), and suppress free radical and inﬂ  ammatory path-
ways in the peripheral vasculature of humans and animal models 
of hypertension and diabetes, thereby restoring vascular function 
(Diep et al., 2002; Bagi et al., 2004; Martens et al., 2005; Hwang 
et al., 2007). PPARγ-induced changes in gene expression include 
upregulation of the O2
·− scavenger, superoxide dismutase1 (SOD1) 
and downregulation of Nox-1, -2, and -4 genes encoding subunits 
of the O2
·−-generating NADPH oxidase (Inoue et al., 2001; Hwang 
et al., 2005, 2007), as measured with real-time PCR. PPARγ may also 
be involved in the induction of oxidative stress-response genes, such 
as heme oxygenase-1 (HO-1) through the nuclear factor E2-related 
factor/antioxidant response element (Nrf2/ARE) pathway, as shown 
in peripheral tissues (reviewed in Kang et al., 2005). The relevance 
of this pathway in the brain and cerebral vessels remains to be 
demonstrated. Moreover, PPARγ ligands can regulate the expres-
sion of ECM molecules, such as CTGF and collagen IV (Fu et al., 
2001; Zaﬁ  riou et al., 2005), which are upregulated in AD brain ves-
sels and implicated in the thickening of cerebrovascular basement 
membranes. Further, PPARγ overexpression or activation with lig-
ands can reduce adhesion molecule and matrix metalloproteinase 
expression and activity in the vasculature, and prevent Rac1 and 
FIGURE 2 | (A) Genetic inactivation of PPARγ in cerebral arterioles (L/+) leads to 
an increase in O2
·− content relative to control vessels (+/+), as detected with 
dihydroethidine ﬂ  uorescence. Bar, 20 µm. Reproduced with permission from 
Beyer et al. (2008) and Wolters Kluwer. (B) Pioglitazone (pio) rescued 
cerebrovascular dilatations to acetylcholine (ACh) and the neurovascular coupling 
response to whisker stimulation in aged APP mice. •, wild-type (WT); {, treated 
WT; S, APP; U, treated APP . Reproduced from Nicolakakis et al. (2008). (C) 
Pioglitazone restored CBF in the parietal and frontal lobes of AD patients in 
single photon emission computed tomography (SPECT) studies. Reproduced 
with generous permission from Sato et al. (2009) and Elsevier.Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 21  |  6
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are known to impair memory. The explanation offered a rationale 
for using rosiglitazone, which may not cross the BBB as readily as 
pioglitazone (Maeshiba et al., 1997), with the authors suggesting 
that rosiglitazone acted on molecules such as insulin and gluco-
corticoids that are capable of penetrating the brain. In APPSwe,Ind 
mice bearing the Indiana (Ind) in addition to the Swedish (Swe) 
APP mutation of Tg2576 mice, rosiglitazone restored perform-
ance in the object recognition and Morris water maze memory 
tests (Escribano et al., 2010). Rosiglitazone also improved per-
formance of APP/presenilin1 (PS1) mice in a modiﬁ  ed version 
of the Morris water maze (Toledo and Inestrosa, 2010). In the 
modiﬁ  ed test, rosiglitazone reduced the number of trials to reach 
criterion (i.e. locate escape platform, <20 s, three successive tri-
als), and harmonized swimming strategies of treated APP/PS1 
mice to those of wild-type counterparts (Toledo and Inestrosa, 
2010). In contrast to the rosiglitazone studies, we have found no 
effect of pioglitazone on memory. This was in spite of positive 
effects on glial cell activation and oxidative stress, and despite 
restored neurometabolic coupling during whisker stimulation, 
as measured with 18F-ﬂ   uorodeoxyglucose positron emission 
tomography (FDG-PET), an indication of restored neuronal 
activity (Nicolakakis et al., 2008). The reason is unknown, but 
it could be related to different properties of the TZD agonists 
used, the advanced age of the animals, shorter treatment dura-
tion (6–8 weeks), insufﬁ  cient cholinergic recovery and residual 
mitochondrial oxidative stress in neuronal perikarya, as detected 
by SOD2 immunostaining. Additional possibilities include the 
use of a stringent Morris water maze test that did not include 
visible platform pretraining, and ﬁ  nally, lack of a pioglitazone 
effect on toxic soluble Aβ oligomers. This is in contrast with the 
lowering of soluble Aβ species by rosiglitazone in the two studies 
reporting cognitive amelioration (Pedersen et al., 2006; Escribano 
et al., 2010; see Table 1). Whether a reduction in Aβ oligomers is 
required for mnemonic improvement is still debated, especially in 
light of the improved Morris water maze performance of elderly 
Tg2576 mice treated with COX-2 inhibitors, yet no reduction in 
levels of soluble and insoluble Aβ1–40/42 or Aβ*56 (Kotilinek et al., 
2008), a 56-kDa Aβ1–42 oligomer linked to the memory deﬁ  cits of 
these mice (Lesné et al., 2006).
The disparate results among mouse studies are made more dif-
ﬁ  cult to interpret since most experiments lack a positive control 
against which to compare PPARγ therapeutic effects. For exam-
ple, it would be desirable to compare the behavioral outcome of 
TZD therapy with that of cholinesterase inhibitors like donepezil 
(Aricept®), rivastigmine (Exelon®) or galantamine (Reminyl®), 
which are currently used to treat mild-to-moderate AD patients. 
Additionally, differences between the mouse models and human 
disease may explain beneﬁ  ts in the former, but not the latter, and 
vice versa. The efﬁ  cacy of compounds in transgenic mouse mod-
els that lack neuroﬁ  brillary tangles and overt neurodegeneration 
(McGowan et al., 2006) may have limited predictive value for AD 
patients. A case in point is the positive outcome with TZDs in clini-
cal trials, despite mixed results in the mouse models. To date, there 
have been two trials with rosiglitazone (Watson et al., 2005; Risner 
et al., 2006), and two with pioglitazone (Hanyu et al., 2009; Sato 
et al., 2009), and the reported beneﬁ  ts after 6 months were often 
comparable to those seen with cholinesterase inhibitors, in terms 
BENEFITS ON NEURONS AND MEMORY
Ultimately, it is hoped that the aforementioned beneﬁ  ts  will 
promote a more favorable environment for neuronal cells, with 
lessened inﬂ  ammatory and oxidative injury, and improved nutri-
ent delivery by the cerebral circulation. PPARγ activation is also 
expected to confer direct protection to neurons from the AD proc-
ess, since they express the receptor, and its activation was shown to 
modulate pathways leading to neurodegeneration (Inestrosa et al., 
2005; Fuenzalida et al., 2007; Pancani et al., 2009). Speciﬁ  cally, ros-
iglitazone and troglitazone prevented Aβ-induced cell death, mor-
phological neurodegenerative changes, and rise in cytosolic Ca2+ in 
rat hippocampal neurons, concomitantly with the restoration of 
cytoplasmic β-catenin levels and inhibition of glycogen synthase 
kinase-3β (GSK3β) activity implicated in τ hyperphosphorylation 
(Inestrosa et al., 2005). The beneﬁ  ts were not seen in the presence 
of the PPARγ inhibitor GW9662, conﬁ  rming that neuroprotec-
tion was mediated by the receptor. In another study, rosiglitazone 
protected hippocampal and dorsal root ganglion neurons against 
Aβ-induced mitochondrial damage and nerve growth factor (NGF) 
deprivation-induced apoptosis, respectively. This was associated 
with upregulation of the anti-apoptotic protein Bcl-2. In the same 
study, PC12 cells constitutively overexpressing PPARγ were resistant 
to Aβ-induced injury and showed no increase in oxidative stress 
following hydrogen peroxide challenge. The cells showed a four to 
ﬁ  vefold increase in Bcl-2 levels, but nearly no Bcl-2 or protection 
against injury when PPARγ or Bcl-2 was inactivated (Fuenzalida 
et al., 2007).
Peroxisome proliferator-activated receptorγ activation was simi-
larly beneﬁ  cial in the streptozotocin-injected rat model of type III 
diabetes. In this model, cerebral insulin is depleted while pancreatic 
insulin is spared, and animals share many features in common 
with AD, including brain insulin resistance, neurodegeneration, 
and impairments in learning and memory. Chronic treatment 
with PPARγ agonists reversed these pathological alterations by 
increasing insulin receptor binding, countering oxidative stress 
and τ phosphorylation, and augmenting choline acetyltransferase 
(ChAT) expression (de la Monte et al., 2006). It also restored glucose 
uptake in brain slices, and improved spatial memory in the Morris 
water maze (Pathan et al., 2006). However, in young TGF mice, 
pioglitazone failed to reverse the TGF-β1-induced decrease in basal 
CGU, and it unexpectedly reduced CGU in the most metabolically 
active brain areas of wild-type mice (Galea et al., 2006), a ﬁ  nding 
that could be related to PPARγ-independent effects on mitochon-
drial function (Feinstein et al., 2005). In this regard, it has been 
postulated that direct binding of PPARγ ligands to mitochondrial 
proteins in a receptor-independent fashion could indirectly cause 
protective changes in gene expression. This would occur through 
a decrease in pyruvate-driven respiration, leading to an increase 
in lactate production, free radicals and oxidative stress, eliciting, 
in turn, a stress response, characterized by increased expression of 
heat shock proteins, as well as anti-inﬂ  ammatory and cytoprotec-
tive genes (Feinstein et al., 2005).
In transgenic AD mouse models with prominent neuronal 
and behavioral deﬁ  cits, 4-month rosiglitazone therapy attenu-
ated cognitive impairments of 13-month-old Tg2576 animals in 
the radial arm maze (Pedersen et al., 2006). It was argued that this 
was due to normalization of increased glucocorticoid levels that Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 21  |  7
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inﬂ  ammation, vascular ﬁ  brosis, amyloid generation, and neuroﬁ  -
brillary tangle formation, PPARγ agonists offer therapeutic poten-
tial against most elements of the AD pathology (Figure 3). However, 
many of the aforementioned effects require further conﬁ  rmation 
in appropriate AD models, and validation in patients. Positive 
cognitive outcomes reported by the ﬁ  rst clinical trials with TZDs 
warrant larger studies to conﬁ  rm whether PPARγ ligands should 
be considered as treatments for AD.
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of point improvement in the Mini-Mental State Exam (MMSE) 
and/or Alzheimer’s Disease Assessment Scale-Cognitive Subscale 
(ADAS-Cog). For example, rosiglitazone improved the ADAS-Cog 
by 2.94 points in mild-to-moderate AD patients lacking the ApoE4 
susceptibility factor (Risner et al., 2006), an improvement well in 
the range of that offered by cholinesterase inhibitors (0.84–3.99 
points) (see references in Risner et al., 2006 and Yoshida et al., 
2007). If larger studies corroborate these ﬁ  ndings, TZDs may be 
considered as primary therapy for patients with diabetes, who 
are at greater risk of developing AD (Ott et al., 1999; Kroner, 
2009) or for diabetic AD patients, who could forego cholineste-
rase inhibitors in favor of compounds that can additionally offer 
glycemic control.
CONCLUSION
The evidence reviewed herein suggests a beneﬁ  cial role of PPARγ 
ligands on the cerebrovascular, glial and neuronal compartments 
affected by the AD process. Through the ability to regulate genes 
implicated in survival, brain glucose metabolism, oxidative stress, 
FIGURE 3 | PPARγ activation could rescue afﬂ  icted vascular, glial, and 
neuronal compartments in the AD brain. Transcriptional suppression of 
inﬂ  ammatory, oxidative, and ﬁ  brotic pathways would reduce tissue injury and 
reinstate adequate substrate delivery by the cerebral circulation. TZDs capable 
of passing the BBB could upregulate anti-apoptotic factors in neurons, 
re-sensitize cells to insulin and restore glucose utilization. The potential to 
counter amyloidogenesis and τ hyperphosphorylation could be disease-
modifying, but requires further empirical support and conﬁ  rmation in patients.Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 21  |  8
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